Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice. - Wikidata - wikimedia - TriplyDB

Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice.

Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice.

http://www.wikidata.org/entity/Q35180081

about

Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence Incretin-Based Therapy for Prevention of Diabetic Vascular Complications GLP-1-based strategies: a physiological analysis of differential mode of action Indirect effects of glucagon-like peptide-1 receptor agonist exendin-4 on the peripheral circadian clocks in mice Exenatide Facilitates Recovery from Oxaliplatin-Induced Peripheral Neuropathy in Rats Cognitive impairment in diabetic patients: Can diabetic control prevent cognitive decline?Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas.Anti-inflammatory effects of exendin-4, a glucagon-like peptide-1 analog, on human peripheral lymphocytes in patients with type 2 diabetes.Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury Contribution of hyperglycemia on diabetic complications in obese type 2 diabetic SDT fatty rats: effects of SGLT inhibitor phlorizin Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis.Metanx alleviates multiple manifestations of peripheral neuropathy and increases intraepidermal nerve fiber density in Zucker diabetic fatty rats.Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders Effects of exenatide on measures of diabetic neuropathy in subjects with type 2 diabetes: results from an 18-month proof-of-concept open-label randomized study Protection of trigonelline on experimental diabetic peripheral neuropathy.Effect of Exendin-4 on Autophagy Clearance in Beta Cell of Rats with Tacrolimus-induced Diabetes Mellitus.Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection.GLP-1 effects on islets: hormonal, neuronal, or paracrine?The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.Extra-pancreatic effects of incretin-based therapies.Activation of Glucagon-Like Peptide-1 Receptor Promotes Neuroprotection in Experimental Autoimmune Encephalomyelitis by Reducing Neuroinflammatory Responses.Impaired Axonal Regeneration in Diabetes. Perspective on the Underlying Mechanism from In Vivo and In Vitro Experimental Studies.Sensory and motor physiological functions are impaired in gastric inhibitory polypeptide receptor-deficient mice.Efficacy of glucagon-like peptide-1 mimetics for neural regeneration.Characterisation of pain responses in the high fat diet/streptozotocin model of diabetes and the analgesic effects of antidiabetic treatments.Transplantation of dental pulp stem cells improves long-term diabetic polyneuropathy together with improvement of nerve morphometrical evaluation.Glucagon-like peptide 1, insulin, sensory neurons, and diabetic neuropathy.The dipeptidyl peptidase IV inhibitor vildagliptin suppresses development of neuropathy in diabetic rodents: Effects on peripheral sensory nerve function, structure and molecular changes.Neurotrophic and neuroprotective properties of exendin-4 in adult rat dorsal root ganglion neurons: involvement of insulin and RhoA.Glucagon-like peptide 1 receptor (GLP-1R) expression by nerve fibres in inflammatory bowel disease and functional effects in cultured neurons.

P2860

Q26739999-A7D34F07-B4B8-4C09-82D5-BDC10AB112FF Q26765470-9D858856-970C-4857-892E-27C05BAE07CF Q26997149-E4972CA1-EA0F-4406-AE20-68F77FDA847B Q27301386-BB9EDD29-ED99-4B66-8FB3-7D6EFDBFDEC8 Q28550675-446E0A66-34EF-4F39-BFE3-56F4E4F2F472 Q33603286-879802FE-3E02-483F-9D53-B82B5F54B0FD Q33603384-A2317946-3555-4BD8-B0EA-323B53909AD5 Q33607642-D072B21B-D056-4B35-91A9-1165BB32CAC7 Q34362412-150BED0B-F1BA-46B5-83CA-5869B7C0D401 Q35594390-F271E96E-4134-4685-8118-083EA3EF6FC6 Q35960169-F9DEF4B3-1323-4F95-9FAB-DD76D3AAEE49 Q36109233-0A99FB25-F687-4689-A701-7ED1884A3E98 Q36166654-94B23543-C04F-4272-B8E9-472D19CCC1DD Q36307536-06AC27E7-9C86-4EE7-B8BA-9FAB473B3E65 Q36477770-2F585F22-B118-46CE-87C4-078EDDBF4999 Q37111103-C139EA78-7A4A-45A2-809C-D11F5BBD7BCE Q38039489-19101933-6AE4-45D8-9748-FB76F8CE03CA Q38123791-DB954E1C-369D-4118-9D4A-0423EBE2DA6D Q38174279-5064A052-53A9-4E74-8316-5756BA6C7C44 Q38194069-24F40338-9C1A-4641-AE55-DE4848E3274E Q38403431-20F38D0A-B73E-4DB7-8685-E9600C40AAC6 Q38756949-139245AA-7157-41DB-9F77-149F6877B198 Q39719357-EAB53627-7595-4FE9-B349-531CFE8FA860 Q41983493-429DDE72-67EF-4E7F-AA2A-B6A2481A276A Q43159888-940CAAC6-F425-41DB-9DEE-6DD60CDD68EE Q47159384-DB145A64-EE97-4BF4-8DC8-9EF55AA4EA2C Q48511577-DE4EC017-6C36-4B74-82FE-686461A514A2 Q48713671-2B8C861D-3382-4516-BA7C-444DF3099B52 Q53486609-F5849473-2696-4372-ABBB-3A40796DAB3E Q55004136-50C95A93-38B2-494C-AAD2-66D2968A6548

P2860

Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice.

http://www.wikidata.org/entity/Q35180081

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice.

@ast

Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice.

@en

type

label

Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice.

@ast

Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice.

@en

prefLabel

Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice.

@ast

Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice.

@en

P1433

Q35180081-05DAB722-A589-4B78-AE3E-2133D8FD6A98

P1476

Q35180081-E9755B95-1A56-46B1-A441-F11CCBEDDBC5

P2093

Q35180081-0C358FFA-014F-49B3-ABF6-E1E15F2EBACB

Q35180081-0F9F0ABF-B6DF-4B95-B371-B25B926F4078

Q35180081-10193C04-7FC1-4504-BBE4-BDF3A4714408

Q35180081-22FDA2D4-8364-4F9C-8685-1A8F31F13172

Q35180081-31690645-5987-4A6B-8571-380C9119B6DC

Q35180081-32E51FBB-4EF8-46FC-8588-FA8215F0D980

Q35180081-55882BDB-CAB4-4133-8800-60F80E0B9FEA

Q35180081-5DDCD092-5C87-4606-B56F-6F7FF6A20DB8

Q35180081-84F772AD-6147-4585-9957-7A4BEF9340C1

Q35180081-88BCC87E-2B1E-4CB4-B813-A70F7F064EAA

P2860

Q35180081-05CB533D-9841-4586-8BAC-A5942BFD3AC3

Q35180081-05E7CFB0-A4D1-4E73-AE91-CA2DA9FC9EEA

Q35180081-09474C5D-F62C-43A8-A373-CBFE86498870

Q35180081-10CB6878-AC95-4CB3-A324-8967F3E7018C

Q35180081-16FE8425-0124-4D80-BB32-A2EDEFD4EA3C

Q35180081-18DA3E1F-175F-4E33-B8AC-827D63859663

Q35180081-1D6A56F9-3309-430E-B7B9-A10EFFA2E1C7

Q35180081-269B5788-89B3-4798-B2C2-6A6988E2434C

Q35180081-278829CB-CC52-43BD-82D7-CEB6F0CF7A1A

Q35180081-28DD18CD-B138-49A0-97C4-8554546DE2A2

P304

Q35180081-98E0317C-57D8-4657-9689-D6A4A0B72EE7

P31

Q35180081-501F4CEF-9EAE-470E-89B6-DECDBB0C8437

P356

Q35180081-95AE6CB7-C3F1-4BD9-882D-E0BB48116A8B

P407

Q35180081-14EB5359-E6A8-4AB8-8B42-C3696EEA6503

P433

Q35180081-46FDEBE7-2554-4479-BA6B-9CD725F37904

P478

Q35180081-4780FEC0-6B15-430F-85FD-3FEB8CC74A71

P50

Q35180081-63E86A64-4D5C-4A1F-87AD-1A59B2101EA5

P577

Q35180081-807A7037-B8AA-480B-BFF4-A439EC042509

P5875

Q35180081-7E2289D7-22DD-4CEE-9B82-5B3F3CA5875A

P698

Q35180081-697B5021-3069-4041-94A8-4FD5CCA8E18D

P932

Q35180081-9280781B-069A-4103-BA36-1CB970EC39FC

P356

P1433

P1476

Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice.

@en

P2093

Ayako Fukami

http://www.w3.org/2001/XMLSchema#string

Hideki Kamiya

http://www.w3.org/2001/XMLSchema#string

Jiro Kato

http://www.w3.org/2001/XMLSchema#string

Jiro Nakamura

http://www.w3.org/2001/XMLSchema#string

Keiko Naruse

http://www.w3.org/2001/XMLSchema#string

Masaki Kondo

http://www.w3.org/2001/XMLSchema#string

Nobuaki Ozaki

http://www.w3.org/2001/XMLSchema#string

Nobuya Inagaki

http://www.w3.org/2001/XMLSchema#string

Norio Harada

http://www.w3.org/2001/XMLSchema#string

Taiga Shibata

http://www.w3.org/2001/XMLSchema#string

P2860

A role for glucagon-like peptide-1 in the central regulation of feeding

Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1

Chemokines and the pathophysiology of neuropathic pain

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

Glucagon-like peptide-1 receptor is involved in learning and neuroprotection

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM

Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis

Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons

Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure.

P304

2397-2406

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DB10-1462

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P50

Daniel J. Drucker

P577

2011-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51541595

http://www.w3.org/2001/XMLSchema#string

P698

21810596

http://www.w3.org/2001/XMLSchema#string

P932

3161330

http://www.w3.org/2001/XMLSchema#string